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ABSTRACT

ARTICLE HISTORY

Interpretation of endpoints (e.g. overall response rate) in clinical trials depends on the accurate
and reliable measurement and identification of tumors. Regulatory agencies recommend blinded
reviews of imaging data by independent review committees (IRCs). Differences in response outcomes that arise between IRCs and site investigators raise regulatory/sponsor concerns. Here, we
evaluate discrepant tumor response assessments by the IRC and unblinded investigators (complete versus partial response, respectively) occurring in 52 (13% of 393 IRC-assessed responders)
of 447 enrolled patients with treatment-naïve non-Hodgkin lymphoma from a randomized study.
The IRC and investigators were ‘likely correct’ in 73% and 25% of cases, respectively (p < .001).
Investigators were more likely to make errors by misinterpreting lymph node data and not utilizing PET results. This post hoc finding suggests a possible role for post-training site evaluation/
audit, with retraining as needed, and a specialized consensus committee for concurrent blinded
review of site/central data.
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Introduction
Overall survival (OS), although widely considered the
gold standard for treatment efficacy of oncology
agents, needs considerable time for data maturation,
and can be confounded by sequential therapy, noncancer deaths, and patient loss to follow-up.[1] To
address these and other concerns, alternate endpoints,
including progression-free survival (PFS), time to progression, and overall response rate (ORR), are used as
efficacy (even as primary) endpoints.[1] These measures, however, are based on interpretation of tumor
response, which has multiple dependencies including
measurement precision, reader perception, inherent
tumor characteristics, manifestations of treatment
effect, image quality, underlying patient condition, and
the response criteria used for assessment.[2,3] Further,
both inter- and intra-reader variability could lead to
‘noise’ in tumor response results.[2] Readers have been
found to differ in the selection of a target lesion and
tumor-margin measurement, particularly with poorly
defined tumors.[4–6]
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Incorporation of blinded independent review committees (IRCs) aims to improve objectivity and reliability of clinical data that might be subject to observer
bias and variability.[7] A prevalent concern is that site
investigators (INVs) may be subject to unintentional
bias by additional patient information or the expected
outcome of the trial.[8] The IRC review process is frequently structured to gain agreement between 2 radiologists well-versed in the study protocol, with
disagreement between initial reviewers adjudicated by
a third reviewer (i.e. ‘2 þ 1’ design).[9] Improvements
in electronic communication facilitate prompt transmission of imaging data; in some cases, real-time
evaluation of imaging data by an imaging core facility
can provide feedback to trial sites.[10]
Recent studies and meta-analyses comparing INV
and IRC imaging assessments found broad consistency
between reviews.[2,8,10–14] However, among the
ongoing debates is whether a threshold rate of discrepancy between INV and IRC assessments, if available, is an adequate indicator of validity of trial results,
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and whether there are specific types of trials for which
an IRC is particularly critical, and those for which an
independent audit may be sufficient.[9,15] Moreover,
understanding how differences in data interpretation
arise could identify future opportunities for improved
processes to minimize inter-reader differences. Some
of the process improvement may include developing
additional guidelines, for use across all sites, that
address specific ambiguous scenarios.
As part of this effort, we conducted an exploratory
review of a subset of discrepant responses (partial
responses [PR] assessed by INVs and complete
responses [CR] assessed by IRC) from the primary data
of a recent first-line clinical trial in non-Hodgkin
lymphoma (NHL). The randomized, noninferiority, global, phase 3 study compared the efficacy and safety of
bendamustine-rituximab (B-R) against standard chemotherapy regimens.[16] Analysis of this study provided
an opportunity to evaluate how differences could arise
between INV and IRC in an active-controlled trial for
which both INVs and IRC received training for objective response measures, specifically the International
Working Group (IWG) response criteria.[16]

Materials and methods
Study design and objectives
The phase 3 study (NCT00877006) was an open-label,
active-controlled, randomized clinical trial designed to
assess noninferiority of B-R compared with standard
treatment regimens of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone
(R-CHOP) or rituximab plus cyclophosphamide, vincristine, and prednisone (R-CVP) in the first-line treatment
of patients with CD-20–positive indolent NHL or mantle cell lymphoma (MCL).[16] The study design, enrollment eligibility criteria, treatment plan, and statistical
analysis have been previously described.[16] The global study was submitted to each institution’s
Independent Ethics Committee or Institutional Review
Board, and all patients submitted written informed
consent.[16,17]
All efficacy response analyses were performed by
the INV and an IRC, and local readers received training
from the sponsor (Appendix). Tumor response was
assessed by the revised IWG response criteria for
malignant lymphoma.[18] This multidisciplinary assessment of response, including radiology and clinical
reviews, incorporates qualitative findings on physical
examination with tumor assessments by computed
tomography (CT) scan, magnetic resonance imaging,
and [18F] fluorodeoxyglucose positron emission
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Table 1. Baseline demographics and clinical characteristics.
Characteristic
Age, median, years (range)
Sex (male/female, %)

Patients (n ¼ 52)
60.5 (37.0–82.0)
37/63

Race, n (%)
White
Asian
Other

47 (90)
1 (2)
4 (8)

Histologic classification, n (%)
Lymphoplasmacytic
Marginal zone
Mantle cell
Follicular, grade 1
Follicular, grade 2
Missing

1
4
11
17
19
1

(2)
(8)
(21)
(33)
(37)
(2)

FLIPI category for patients with follicular lymphoma, n (%)
Low risk
11 (21)
Intermediate risk
10 (19)
High risk
15 (29)
FLIPI score, n (%)
0
1
2
3
4
5

2
9
10
12
2
1

(4)
(17)
(19)
(23)
(4)
(2)

IPI category, n (%)
Low risk
Low-intermediate risk
High-intermediate risk
High risk

18
18
14
2

(35)
(35)
(27)
(4)

B symptom present, n (%)
Yes
No
Unknown
Age at onset, median, years (range)
Median time from diagnosis, months (range)
Baseline ECOG performance status, n (%)
0
1
2
Median time from most recent biopsy
(not bone marrow), months (range)
PET data available

18
32
2
59.0
1.5

(35)
(62)
(4)
(37.0-82.0)
(0.1-86.2)

37 (71%)
15 (29)
0
1.0 (0.1–5.4)
16 (31)

ECOG: Eastern Cooperative Oncology Group; FLIPI: Follicular Lymphoma
International Prognostic Index; IPI: International Prognostic Index; PET:
positron emission tomography.

tomography (PET) when available, and results from
immunohistochemistry and flow cytometry on tumor
pathologic specimens from bone marrow biopsies and
aspirates.[18] CR rates were also compared among
treatment groups by preplanned subgroups defined
by Follicular Lymphoma International Prognostic Index
(FLIPI) risk score and bulky-disease status (i.e. tumor
diameter 3 cm in 3 regions or diameter 7 cm in 1
region).[19] Patient baseline characteristics are summarized in Table 1.

Evaluation of patient-level divergent
interpretations in tumor response
A post hoc analysis was performed on a subset of
patients in the study with best response assessed as
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PR by site INVs and CR by IRC. There were relatively
few differences in assessments for other types of
response, such as stable disease and progressive disease, and they were not assessed in this review due to
resource constraints. The purpose of this review was
to understand the reasons for the divergent interpretations and to identify opportunities for improvement
so as to minimize differences in the future. This retrospective subanalysis was performed across all treatment groups by a consensus of 3 independent
reviewers, 2 of whom each have 30 years of experience in the field of clinical trials using oncology
imaging, and a postgraduate year-3 radiology resident who were blinded to treatment (to avoid potential bias) and were not part of the IRC, study, or
participating sites. Available data included: index and
non-index lesions and corresponding anatomic site
codes, as well as lesion measurements; response
assessment at each time point; the presence/absence
of new lesions; and selected clinical information (e.g.
bone marrow biopsy results, clinical symptoms, presence of hepatosplenomegaly, or individual lesions
selected by the INV during the physical exam).
Collection of PET data was optional as per the protocol, but, if performed, INV and IRC radiologists were
required to include these data in assessing response.
Index lesions were selected independently by the INV
and IRC. Annotated files containing images marked
with measurements were created and stored by IRC
radiologists; however, the measurements provided by
trial sites were not recorded with the image to indicate exactly what was measured. Therefore, inaccurate measurements and lesion selection errors could
not be detected for INV, which could have biased
this analysis against the IRC.
A complete review of all lesions and measurements
was not performed, and therefore, lesion selection and
measurements were initially assumed to be accurate
as provided, and the nomenclature of ‘likely correct’
best response was adopted rather than ‘true correct
best response’ given the available data and review limitations. Despite this planned methodology, obvious
errors in lesion measurement were noted during this
imaging review, and any corresponding changes in
best response were acknowledged. In cases where
both the INV and IRC reached a logically sound, but
discrepant, best response based on data they included
in their assessment, an additional image review was
performed to determine if either assessment could be
considered more accurate. This largely involved
reviewing different anatomic site codes to determine if
persistent abnormal lesions existed in those locations,
which in turn would prevent a PR from being

upgraded to CR. Specifically, if the image review identified any abnormal lymph node in the discrepant anatomic location, the PR was assessed as the ‘likely
correct’ response, which was the most common reason
for an IRC-assessed CR to be downgraded to PR.
Several types of error were considered for inclusion
in this review. Random error cannot be controlled and
is assumed to be similar in the IRC and INV groups.
Human error can include, but is not limited to, lesions
that are missed during the assessment, incorrectly
measured, and/or incorrectly selected as index lesions
by either the IRC or INV. The extent of human error
cannot be fully assessed, however, without a complete
review of all time points for accuracy in all aspects of
outcome assessment (essentially determining a ‘gold
standard’). As this approach was beyond the scope of
this review, the contribution of human error was not
assessed and was assumed to be similar between the
IRC and INV radiologists. This study therefore aims to
isolate the degree to which INV and IRC review processes are themselves subject to error.
Multiple types of errors fell under the umbrella
term of ‘Process error’. A ‘Process’ error, defined as a
data inclusion, application, and/or conclusion error,
serves as a comparative measure between IRC and INV
review methodologies. ‘Data inclusion’ errors were
defined as a failure to incorporate available image
data or clinical information into the response assessment. An ‘Application’ error was defined as incorrect
application of the study protocol, response criteria, or
response assessment (e.g. index/non-index disease
does not meet inclusion criteria; only the percentage
change in sum of product of the diameters (SPD) was
considered instead of appropriate criteria for lesion
type/number; failure to consider if lymph nodes
returned to normal size before assigning best
response; and failure to consider clinical data in best
response assignment). A ‘Conclusion’ error was considered as a subset of application error, and results from
arriving at the incorrect response conclusion based on
the intrinsic data considered.

Results
Patient-level divergent interpretations in tumor
response
A post hoc analysis of the study data set identified 52
patients whose best tumor response was categorized
differently by IRC (CR) and INV (PR); these 52 patients
represented 13% of the 393 IRC-assessed responders.
Review of these cases based on available data found
the IRC was ‘likely correct’ in 73% of discordant cases,
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Table 2. Attributions of patient-level divergent interpretations
(n ¼ 52) in tumor response.
‘Likely Correct Best Response’ in discordant
casesa
Process errorb
Data inclusion error
Application error
Conclusion error

INV

IRC

p Valuec

25%

73%

<.0001

79%
31%
56%
41%

4%
0
6%
4%

<.0001
<.0001
<.0001
<.0001

INV: investigator; IRC: independent review committee.
a
In one case, both the INV and IRC were ‘likely correct’, depending on
which lesions were measured.
b
More than one error was observed in some cases. ‘Process errors’ are
defined as errors of inclusion, application, and/or conclusion. They are
generally characterized as any errors primarily attributed to the process
of image acquisition, distribution, and review, as well as response criteria
application, but they would not include such errors as differences related
to lesion choice, lesion/mass measurement, random chance, or failure to
assess minimal residual disease in the bone marrow/blood. ‘Data inclusion error’ results from failure to incorporate available data/information
into response assessment; primarily derived from failure to include positron emission tomography data when available. ‘Application error’ is
defined by incorrect application of study protocol, response criteria, and
response assessment. ‘Conclusion error’, a subset of application error,
results from arriving at incorrect conclusion of response based on the
intrinsic data considered.
c
Fisher’s exact test.

and the INV were ‘likely correct’ in 25% of discordant
cases (p < .0001). In one discordant case (2%), the outcome difference was driven by alternative index lesion
selection, without subsequent obvious errors in measurement, data acquisition, or the application of
response criteria. As a result, neither the IRC nor the
INV outcome could be judged as being incorrect.
Some discordant cases were associated with more
than one error (Table 2). In 48% of discordant cases,
the INV failed to consider that pathologic lymph nodes
had returned to normal size, and erroneously assigned
a best response of PR instead of CR according to the
response criteria. Additionally, in 31% of discordant
cases, the INV did not apply available PET data, which
was required by the protocol. Relevant clinical data
were applied incorrectly by the IRC in 6% of discordant cases. Incorrect lesion measurements were incidentally detected during additional image review in 12%
and 17% of discordant cases for the IRC and INV,
respectively.
The most common errors were ‘Application Errors’
(56% and 6% of INV and IRC tumor response interpretations, respectively) and occurred when the original
pathologic index lesions returned to normal size at follow-up as defined by the study criteria, resulting in a
‘likely correct’ assessment of CR by the IRC. In these
cases, the INV typically incorrectly assessed PR based
on a reduction of greater than 50% in the SPD of the
index lesions, while not accounting for the fact that all
pathologic lesions returned to normal size. In 4 application-error cases, the IRC failed to downgrade CR to
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PR when bone marrow was involved at baseline but
bone-marrow biopsy was not repeated at clinical CR.
‘Data Inclusion Error’ was another common error (31%
and 0% of INV and IRC tumor response interpretations,
respectively) and was seen when there were
PET-negative residual nodal masses at follow-up that
retained pathologic measurements. In these 15 cases,
PR was incorrectly assessed by the INV despite the
availability of relevant PET data, which would necessitate assigning CR to lesions that demonstrate resolution of hypermetabolic activity regardless of size.
Although it was not the main goal of the study,
human error was observed during image review. As an
example, a patient was enrolled with an abnormal
supraclavicular lymph node at screening. Though the
lymph node returned to normal size by cycle 6 as confirmed on image review, it was measured as abnormal
by the INV, thus resulting in an incorrect assignment
of PR as opposed to a valid CR. Another example
involved a patient with extensive retroperitoneal/perivascular disease at screening. Although consensus
imaging review confirmed that disease had resolved at
cycle 8, multiple INV measurement errors incorrectly
resulted in INV classification as PR instead of the correct outcome of CR as assessed by the IRC. As an
example of an IRC human error, a patient had splenomegaly with an abnormal heterogeneous enhancement pattern at screening. The spleen later
demonstrated a normal CT enhancement pattern at
follow-up but remained enlarged. Though the IRC
erroneously assigned a time point response of CR, the
‘likely correct’ response was determined to be PR due
to persistent splenomegaly.

Consideration of clinical relevance of discordant
assessments: trends in IRC and INV assessments of
tumor response in the full study population
The full efficacy and safety analyses from this study
have been previously described.[16,17] Across the full
data set from the study, the IRC study assessed the CR
rate at 31% (95%CI 25.3–38.2%) in the B-R group and
25% (95%CI 19.5–31.7%) in the R-CHOP/R-CVP groups.
In the primary analysis for noninferiority (margin 0.88),
the p value was .022, indicating statistical noninferiority between the two treatments. Site INVs reported
fewer CR in the R-CHOP/R-CVP group, increasing the
margin between the study groups: 31% (95%CI
24.8–37.7%) in the B-R group and 19% (95%CI
14.2–25.5%) in the R-CHOP/R-CVP group. Analysis of
these data demonstrated noninferiority (p ¼ .002),
which paralleled the IRC findings.[16] The p value for
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Table 3. Best overall response by INV compared with IRC.
Evaluable patients (%) in the study

Investigator assessment (%) (read across)
CR
PR
SD
PD
CPD
UN
IRC Total

BR treatment group (n ¼ 213)

R-CHOP/R-CVP group (n ¼ 206)

IRC assessment (%) (read down)

IRC assessment (%) (read down)

CR

PR

SD

PD

CPD

UN

INV total

CR

PR

SD

PD

CPD

UN

INV total

19
12
<1
0
0
0
31

12
52
1
0
0
<1
65

<1
2
0
0
0
0
3

0
<1
0
0
<1
0
<1

0
0
0
0
0
0
0

0
0
0
0
0
0
0

31
66
2
0
<1
<1

12
13
0
0
0
0
25

6
56
3
0
0
0
66

1
4
2
<1
0
0
9

0
0
0
0
0
0
0

0
0
0
0
0
0
0

0
0
0
0
<1
0
<1

19
74
6
<1
<1
0

BR: bendamustine and rituximab; CPD: clinical progressive disease; CR: complete response; INV: investigator; IRC: independent review committee; PD: progressive disease; PR: partial response; R-CHOP: rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone; R-CVP: rituximab plus cyclophosphamide, vincristine, and prednisone; SD: stable disease; UN: unknown.

superiority was .005, which was significant, in contrast
to the IRC analysis.[16]
There was greater difference between the INV- and
IRC-assessed tumor responses in the R-CHOP/R-CVP
group than in the B-R group. In the R-CHOP/R-CVP
group, the IRC measured more CR than INV (25% vs.
19%, respectively). Correspondingly, the PR rates determined by IRC and INV were 66% and 74%, respectively, for the patients receiving standard therapy. In
the B-R group, both the INV and IRC assessed the CR
rate to be 31%, and the PR rates were 66% and 65%
by the INV and IRC, respectively. The proportions of
patients with better tumor response when measured
by IRC compared with INV were 15% in the B-R group
and 17% in the R-CHOP/R-CVP group (Table 3, bold
numbers). INV-assessed CR was downgraded in the
subanalysis to PR in 12% of patients receiving B-R and
6% of patients receiving R-CHOP/R-CVP. The proportions of patients with a poorer tumor response when
measured by the IRC compared with INV were 15% in
the B-R group and 12% in the R-CHOP/R-CVP group
(Table 3, italicized numbers). The IRC upgraded INVassessed response to CR in 12% of patients receiving
B-R and 13% of patients receiving R-CHOP/R-CVP.

Discussion
The objective of this exploratory analysis was to evaluate causes of discordance between INV and IRC tumor
assessments from a phase 3 study in advanced indolent NHL or MCL. Although the INV and IRC assessed
similar rates of tumor response in the trial, this caseby-case comparison of the 52 patients whose data
were interpreted differently (out of 447 patients) provides a qualitative look at how errors are introduced
into clinical trial data. More precisely, in this response
data set, site INVs categorized patients as PR and the

IRC categorized patients as CR. Overall, we found that
site INVs made significantly more process errors than
the IRC (p < .0001). Errors occurred in the IRC process
as well, although to a smaller extent. Although the differences affected a small proportion of the study
population, the potential exists for these errors to
affect data analysis and interpretation.
In this analysis, we have focused on the types of
error that occur in interpreting clinical and imaging
data for the determination of tumor response in clinical trials. Although the data set reported here was
not suitable to completely and prospectively analyze
human and random errors, these errors likely occur at
similar frequencies in both review processes, and
would presumably contribute equally to the data set.
Our analysis indicates that INVs are more prone to
process errors than a blinded IRC, with INV errors
occurring in approximately 73% of discrepant cases.
The majority of these errors reflected the lack of
incorporation of available critical data (in particular,
available PET data) or incorrect application of response
criteria (in particular, only considering reduction in the
SPDs and failure to include that lymph node returned
to normal size; thus, a best response of PR rather than
CR is assigned per response criteria), and thus the
INVs did not arrive at the correct conclusion during
the response assessment. These process errors may be
attributed to the incorrect selection or misinterpretation of imaging data, and may reflect selection bias.
Measures to address these errors might include additional risk-based monitoring, without breaking the
blind, to minimize inter-reader differences. Whether
the errors were equally distributed across all INV sites
or clustered at a few sites was not assessed, but could
be seen as an opportunity for an additional risk-based
monitoring. It should be pointed out that as the
measurements provided by trial sites were not
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recorded with the image to indicate exactly what
were measured, inaccurate measurements and lesion
selection errors could not be detected for INV, which
could have biased this analysis against the IRC.
In this study, both INV and IRC results supported
the primary endpoint. Of note, however, there was a
trend for more discordance between INV and IRC
assessments in the R-CHOP/R-CVP group than in the BR group. Although the cause of this difference is
unknown, possible factors might include that tumor
progression is subject to time bias, and studies with
different schedules of disease assessments may be
more prone to variability between treatment arms.[20]
In this study, the treatment cycles were 28 and 21
days for the B-R and R-CHOP/R-CVP regimens, respectively.[16] Unblinded observer bias is an additional
possibility.
These data about process errors add granularity to
the previously published analyses comparing the data
reported by INVs and IRCs from other cancer trials.[8,11–13] Meta-analyses have shown modestly, but
generally higher PFS rates reported by INVs compared
with IRCs,[11,13] but one, which also compared
response rates, reported that aggregate results across
studies were similar between INVs and IRCs, although
there were wide variations among the component trials.[11] Because the response rate analysis did not
evaluate the differences in the qualification of the
response in the 18 trials with response rate as the primary endpoint in the meta-analysis, a direct comparison between that paper and our analysis cannot be
made.[11] However, the authors of these analyses
have generally recommended the use of a blinded IRC
if the primary endpoint is changes in tumor response,
or in cases where there are potential local INV biases
due to the nature of the trials (e.g. unblinded trial
where a small effect on PFS is observed).[8,11,13] This
observation, however, was not extended to PFS.
Median PFS reported by the INVs was equally likely to
be longer or shorter than the reported IRC data in the
trials included in the meta-analyses, suggesting little
to no bias by the INV, although this finding may vary
between tumor types and available treatments.[11,12]
This finding has been interpreted to indicate an inherent variability in the process of measuring PFS at the
patient level. Regulatory authorities currently consider
the relative treatment effect across the study population, which modulates the variability, rather than analyzing patient-level data.[12] However, high-quality raw
data are necessary to properly assess the efficacy of
oncology treatments, particularly as more agents
become available through development pipelines. The
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impact of data errors on the treatment effects
reported by INV without an IRC review is unknown.
Although this analysis is post hoc, these data provide insight into the strengths and weaknesses of INV
and IRC outcomes, and provide an opportunity to consider methods to reduce error. We recommend the
incorporation of an IRC for most, if not all, large clinical trials studying tumor response, as well as a consensus committee where both the site and central
data are reviewed concurrently when possible. This
approach could be used to monitor site performance,
while providing context for observed divergent interpretations for INVs, sponsors, and regulators. A higher
level site training may reduce rates of process errors;
however, site staff turnover is at a potential complication. Application errors could be addressed by better
application of the study protocol and staging and
response criteria. Similarly, training may reduce errors
that occur in the IRC process. Monitoring reader performance is an important part of the IRC process.
Improvements in imaging may reduce variability as
well. The 2014 Lugano classification system emphasizes accurate imaging with PET-CT scans, which can
improve the accuracy of staging treatment selection
and measuring treatment response for patients with
NHL.[21] Future clinical trials that incorporate these
standards, especially when images are taken with
high-quality calibrated scanners, may have higher consistency between INV and IRC assessments.
Large multicenter clinical trials are the best mechanism for evaluating the efficacy and safety of oncology drugs. The decentralized designs, however, are
only as strong as the quality of each study site. Our
data emphasize the importance of an IRC in oncology
trials, and for additional review of data to evaluate site
performance and identify points for improvement.
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Appendix
Response definitions from the study protocol. The IRC conducted its reviews according to a charter. Per the nature of
charters, it was more detailed than the following definitions
in the protocol, which were provided to the investigators
and the IRC.

Complete response (CR)
The designation of CR requires the following:
 There must be complete disappearance of all detectable
clinical evidence of disease and disease-related symptoms, if present before therapy.
 PET scan assessment criteria are as follows:
– If the pretreatment PET scan was FDG avid/positive, a
residual mass of any size on a post-treatment CT is
permitted when the corresponding PET scan is FDG
negative.
– If the pretreatment PET scan was not performed but
the patient has a lymphoma subtype which is typically
FDG avid/positive, a residual mass of any size on a
post-treatment CT is permitted when the corresponding PET scan is FDG negative.
– If the pretreatment PET scan was FDG negative, all
lymph nodes and nodal masses must have regressed
to normal size. All nodes/masses greater than 1.5 cm
(long axis) pretreatment must have decreased to
1.5 cm (long axis) or less post-treatment. All nodes/
masses of 1.1–1.5 cm (long axis) and greater than
1.0 cm (short axis) pretreatment must have decreased
to 1.0 cm (short axis) or less post-treatment.
– If the pretreatment PET scan was not performed and
the patient has a lymphoma subtype for which FDG

NON-HODGKIN TUMOR RESPONSE ASSESSMENTS

avidity is either unknown or variable, all lymph nodes
and nodal masses must have regressed to normal
size. All nodes/masses greater than 1.5 cm (long axis)
pretreatment must have decreased to 1.5 cm (long
axis) or less post-treatment. All nodes/masses between
1.1–1.5 cm (long axis) and greater than 1.0 cm (short
axis) pretreatment must have decreased to 1.0 cm
(short axis) or less post-treatment.
 If the spleen and/or liver are enlarged on the basis of
physical examination and/or anatomic imaging (CT and/
or MRI) before treatment, the liver and/or spleen should
be considered normal size on physical examination and
by anatomic imaging after therapy, with disappearance
of all nodules related to lymphoma.
 If the bone marrow was involved by lymphoma before
treatment, the infiltrate must have cleared on subsequent bone marrow biopsies. The biopsy sample on
which this determination is made must be adequate
(with a goal of greater than 20 mm unilateral core). If
the sample is indeterminate by morphology, it should
be negative by immunohistochemistry. A sample that is
negative by immunohistochemistry but that demonstrates a small population of clonal lymphocytes by flow
cytometry will be considered a CR until data become
available demonstrating a clear difference in patient
outcome.

Partial response (PR)
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 In patients with follicular lymphoma or mantle cell
lymphoma, a PET scan is only indicated with 1 or at most
2 residual masses that have regressed by more than 50%
on CT; those with more than 2 residual lesions are
unlikely to be PET negative and should be considered
partial responders.

Stable disease (SD)
The designation of SD requires the following:
 A patient is considered to have SD when he or she fails
to attain the criteria needed for a CR or PR, but does not
fulfill those for progressive disease.
 Typically FDG-avid lymphomas: the PET should be positive at prior sites of disease with no new areas of involvement on the post-treatment CT or PET.
 Variably FDG-avid lymphomas/FDG-avidity unknown: for
patients without a pretreatment PET scan or if the pretreatment PET was negative, there must be no change in
the size of the previous lesions on the post-treatment CT
scan.

Relapsed disease (after complete response)/
progressive disease (after partial response, stable
disease)

The designation of PR requires the following:

Relapsed disease (after CR) and progressive disease (PD)
(after PR or SD) requires the following:

 There must be at least a 50% decrease in the sum of the
product of the diameters (SPD) of up to 6 of the largest
dominant nodes/masses. (Nodes selected pretreatment
should be clearly measurable in at least 2 perpendicular
dimensions from disparate regions/anatomic sites including the nodes from the mediastinum and retroperitoneum when possible.)
 There must be at least a 50% decrease in the SPD of hepatic and splenic nodules in their greatest transverse
diameter.
 There must be no increase in the size of the liver, spleen,
and other nodes.
 There must be no measurable disease in organs other
than the liver or spleen.
 Bone marrow assessment is irrelevant for determination
of a PR if the sample was positive before treatment. A
clinical CR with persistent morphologic bone marrow
involvement will be considered a PR. A clinical CR with
no post-treatment bone marrow evaluation will be considered a PR.
 No new sites of disease should be observed.
 Typically FDG-avid lymphoma: for patients with no pretreatment PET scan or if the PET scan was positive before
therapy, the post-treatment PET should be positive in at
least 1 previously involved site.
 Variably FDG-avid lymphomas/FDG avidity unknown: for
patients without a pretreatment PET scan, or if the PET
scan was positive before therapy, the post-treatment PET
should be positive in at least 1 previously involved site.

 Lymph nodes should be considered abnormal if the long
axis is greater than 1.5 cm regardless of the short axis. If
a lymph node has a long axis of 1.1–1.5 cm, it should
only be considered abnormal if its short axis is greater
than 1.0 cm. Lymph nodes measuring 1.0 cm by 1.0 cm or
less will not be considered as abnormal for relapse or
progressive disease.
 There must not be any new lesion more than 1.5 cm in
any axis during or at the end of therapy, even if other
lesions are decreasing in size. Increased FDG uptake in a
previously unaffected site should only be considered
relapsed or progressive disease after confirmation with
other modalities. In patients with no prior history of pulmonary lymphoma, new lung nodules identified by CT
are mostly benign. Thus, a therapeutic decision should
not be made solely on the basis of the PET without histologic confirmation.
 There must be at least a 50% increase from nadir in the
SPD of any previously involved nodes, or in a single
involved node, or the size of other lesions (e.g. splenic
or hepatic nodules). To be considered progressive disease, a lymph node with a diameter of the short axis of
less than 1.0 cm must increase by 2: 50% and to a size
of 1.5 cm by 1.5 cm, or more than 1.5 cm in the long
axis.
 There must be at least a 50% increase in the longest
diameter of any single previously identified node more
than 1 cm in its short axis.
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 Lesions should be PET positive if observed in a typical
FDG-avid lymphoma or the lesion was PET positive
before therapy unless the lesion is too small to be
detected with current PET systems (<1.5 cm in its long
axis by CT). Measurable extranodal disease should be
assessed in a manner similar to that for nodal disease.
For these recommendations, the spleen is considered
nodal disease. Disease that is only assessable (e.g. pleural
effusions, bone lesions) will be recorded as present or
absent only, unless, while an abnormality is still noted by
imaging studies or physical examination, it is found to be
histologically negative.

performed with oral contrast. The CT scans may be performed only with oral contrast if a patient is allergic to IV
contrast agents.

[l8F]-fluorodeoxyglucose (FDG) positron-emission
tomography (PET)
A PET scan with [l8F] FDG extending from the neck through
the mid-thighs may be performed to assess baseline disease
at screening and to assess disease response at any time at
the investigator’s discretion.

Bone marrow biopsy and aspirate
Assessment of response
Each investigator will assess disease response (CR, PR, SD,
PD, or relapsed disease) at the end of cycles 3 and 6 and at
the end of cycle 8, if applicable. The investigator should use
the same modality used at baseline to assess both measurable and assessable disease throughout and at the end-oftreatment visit. Tumor assessments should incorporate findings from physical examination, CT scan, MRI, [18F] FDG PET,
immunohistochemistry, flow cytometry, molecular genetics
when appropriate on tumor tissue, and bone marrow biopsies/aspirates.
The use of PET for response in this study is optional
and at the discretion of the investigator. If used, PET
scans may be obtained as a stand-alone scan or with CT
or MRI integration. If PET scans are not utilized, response
should be assessed as above, but only using CT scans.
However, residual masses should not be assigned unconfirmed CR (CRu) status, but should be considered partial
responses.

Computed tomography (CT) scans or magnetic
resonance imaging (MRI)
CT scans or MRI of the neck, chest, abdomen and pelvis
will be performed to assess extent of disease at baseline
(CT scans or MRI performed during screening are acceptable as the baseline scan if completed within 6 weeks prior
to the first study treatment), and any response or progression of disease at cycles 3, 6, and 8, if applicable, and at
any time at the investigator’s discretion.
All CT scans should be performed with intravenous (IV)
contrast, and abdominal and pelvic CT scans should be

A bone marrow aspirate and biopsy sample will be obtained
up to 60 days prior to the first dose of study drug treatment.
Initial bone marrow examinations should establish the presence of disease involvement, if any. Adequate immunophenotyping to establish disease in the bone marrow
pretreatment (within 60 days prior to study drug) should be
performed at baseline and with any subsequent bone marrow evaluations.
The bone marrow must be repeated at the time of a clinical CR, if the baseline bone marrow was positive (evidence
of lymphoma), or was insufficient or indeterminate. If the
bone marrow was involved at baseline and not repeated at
the time of a clinical CR, the best possible response is a PR
at that time point.
If a patient was known to have follicular lymphoma and
B-cell lymphoma/leukemia 2 (BCL-2) positivity in the bone
marrow at baseline, an assessment of BCL-2 on any subsequent bone marrow evaluations is suggested. Cytogenetics
or fluorescence in situ hybridization (FISH) for t(14;18) and
t(8;14) and/or variants and molecular genetic analysis to
detect antigen gene receptor rearrangement/BCL-2
rearrangement is suggested but not required.
If a patient was known to have mantle cell lymphoma
and cyclin D1 positivity in the bone marrow at baseline, an
assessment of cyclin D1 on any subsequent bone marrow
evaluations is suggested. Cytogenetics or FISH for t(11;14)
and t (14;18) and/or variants and molecular genetic analysis
to detect antigen gene receptor rearrangement/bcl-1
rearrangement is suggested but not required.
Standard bone marrow procurement procedures will be
followed for the collection of tissue. The bone marrow
should be reviewed by the hematopathologist/oncologist for
morphologic assessment, flow cytometry, and cytogenetics.

